Blog
RSS FeedPosted by Michael Wonder on 03 Jul 2018
ICER's final report on CGRP inhibitors for migraine prevention explores specific coverage policy options in light of responsible manufacturer pricing
3 July 2018 - Report notes the significant remaining uncertainty about the long-term safety of CGRP inhibitors given their new mechanism ...
Posted by Michael Wonder on 16 Jun 2018
ICER report questions the adequacy of evidence on overall health benefit of elagolix given limitations of information on safety and limited evidence comparing to other treatment options
15 June 2018 - The emerging drug may be cost-effective compared to no treatment if priced in line with analyst ...
Posted by Michael Wonder on 12 Jun 2018
ICER's updated assessment of new targeted therapies for plaque psoriasis notes minor distinctions in effectiveness, while recent price hikes have made entire drug class less cost-effective
12 June 2018 - Value-based price benchmarks for new IL-23 agents range from $25,000-$42,000 per year, which would require a discount ...
Posted by Michael Wonder on 07 Jun 2018
ICER's final report on CFTR modulators for cystic fibrosis calls for manufacturer restraint and increased transparency in pricing decisions
7 June 2018 - Pricing overreach harms people with cystic fibrosis and threatens the health care system's ability to support future ...
Posted by Michael Wonder on 31 May 2018
ICER finds price of erenumab aligns with clinical benefit in patients for whom other therapies have failed to prevent migraines
31 May 2018 - Clinical benefits similar to other new CGRP inhibitors included in review. ...
Posted by Michael Wonder on 05 May 2018
Watchdog says Vertex cystic fibrosis drugs are not cost effective, but company calls analysis a ‘sham’
4 May 2018 - The oldest Vertex drug for cystic fibrosis, Kalydeco, lists for $311,000, while the newer treatment Orkambi lists ...
Posted by Michael Wonder on 24 Mar 2018
ICER final report on CAR-T therapies highlights need for systemwide changes to ensure affordability and access to innovative, one-time therapies
23 March 2018 - Policy recommendations highlight that even though the pricing of current CAR-T therapies aligns with patient benefit ...
Posted by Michael Wonder on 15 Mar 2018
ICER finds emicizumab reduces treatment cost while improving health of people with haemophilia A
15 March 2018 - Report will be subject to public deliberation during New England CEPAC meeting on 29 March 2018. ...
Posted by Michael Wonder on 11 Mar 2018
Institute for Clinical and Economic Review updates value-based price benchmark for alirocumab, a PCSK9 inhibitor for treatment of high cholesterol
10 March 2018 - Based on the results of the ODYSSEY Outcomes trial, ICER has calculated two updated value-based price benchmarks, ...
Posted by Michael Wonder on 18 Feb 2018
ICER report finds costs of approved CAR-T therapies align with clinical benefit
15 February 2018 - Report will be subject to public deliberation during CTAF meeting on 2 March 2018. ...
Posted by Michael Wonder on 14 Feb 2018
ICER final report: broader benefits of voretigene neparvovec to affected individuals and society provide reasonable long-term value despite high price
14 February 2018 - Appraisal committee vote reveals differences in judgments on value given pricing far above traditional cost-effectiveness levels. ...
Posted by Michael Wonder on 29 Jan 2018
Roche haemophilia drug lowers costs despite high price: ICER
27 January 2018 - A costly new Roche Holding AG drug to treat the bleeding disorder haemophilia A could significantly reduce ...
Posted by Michael Wonder on 13 Jan 2018
Institute for Clinical and Economic Review Report on voretigene neparvovec suggests substantial price discount needed to meet traditional cost-effectiveness standards
12 January 2018 - Special considerations include patient age, benefit durability, and rarity of condition. ...
Posted by Michael Wonder on 22 Nov 2017
Institute for Clinical and Economic Review report finds evidence limited on treatments for tardive dyskinesia; discounts of up to 90% needed to align cost of drugs with benefit to patient
21 November 2017 - Report will be subject to public deliberation during New England CEPAC meeting on 5 December 2017. ...
Posted by Michael Wonder on 06 Nov 2017
Institute for Clinical and Economic Review final report recommends enhanced coverage of certain non-drug management options for chronic low back pain
6 November 2017 - Evidence suggests safe and effective treatments include acupuncture, cognitive behavioral therapy, mindfulness-based stress reduction, and yoga. ...